The video animations for the episodic migraine studies (Animation 1) and for the chronic migraine study (Animation 2) tracks the change in monthly total pain burden as a percent of baseline (y-axis) for each patient in the placebo (left, grey circles) and the galcanezumab 120 mg (right, red circles) group. The x-axis shows individual patients rank ordered by their final percent of baseline value at Month 6 for episodic migraine studies (Month 3 for chronic migraine study), ordered from greatest improvement on the left to greatest worsening on the right within each plot). Patients with missing data during the last month are placed towards the upper end of the x-axis. All patients start at a baseline of 100%. The solid purple line represents the mean percent of baseline in total pain burden within each treatment group at any point in time. In each scatterplot, black dotted reference lines are shown for baseline (100%) and 50% reduction from baseline in total pain burden. Any patient with a percent of baseline value below 100% has shown an improvement in total pain burden from baseline while patients with values below the 50% reference line have shown at least a 50% reduction in total pain burden compared to their baseline score. The bar plot in the middle shows the observed mean change in total pain burden from baseline to the end of each month for each treatment group (placebo, grey, left vs. galcanezumab 120 mg, red, right). The timeline bar across the top tracks the month of treatment being shown, from baseline (Month 0) to Month 6 for episodic (Month 3 for chronic) in the double-blind treatment phase.